Tidepath

Melanocortin peptides

Setmelanotide

Also called Imcivree, setmelanotide acetate

An approved daily injection for obesity caused by an underactive hunger pathway in the brain, not for obesity in general1.

Status
Approved by the FDA in 2020, as Imcivree, for obesity caused by certain genetic conditions; acquired hypothalamic obesity was added in March 2026278.
How it's taken
By injection

What it is

Imcivree is the brand name for setmelanotide, an injection approved for a few kinds of obesity that have a known cause1. It's an MC4 receptor agonist, meaning it switches on the MC4 receptor (melanocortin 4 receptor), part of a pathway in the brain that helps control hunger, fullness and how much energy the body uses1. In the conditions it's approved for, that pathway isn't switched on enough, because of a gene change or damage to the hypothalamus, a small area deep in the brain15. Setmelanotide is a short, ring-shaped peptide modelled on alpha-MSH, one of the body's own melanocortin hormones1. It also acts, more weakly, on a receptor in the skin's pigment cells, which is how it can darken skin1. Its half-life, the time it takes for half a dose to clear, is about 11 hours1. It has been authorised in the European Union since 20216.

What makes it distinct

It's approved only for obesity with a known cause in this pathway: Bardet-Biedl syndrome, a rare genetic condition; POMC, PCSK1 or LEPR deficiency, changes in genes the pathway depends on, confirmed by a genetic test; or acquired hypothalamic obesity, which follows a tumor, lesion or injury affecting the hypothalamus145. Its label says it isn't expected to work for other kinds of obesity, including general obesity1.

What the evidence shows

Its label describes trials in each condition it's approved for1. Two phase 3 trials in people with POMC or LEPR deficiency reported on 10 and 11 people over about a year, with no comparison group apart from a short blinded switch to placebo partway through for those who had lost weight3. In both trials, people lost weight over the year on average, and hunger scores fell in those who rated their hunger13. In a phase 3 trial in Bardet-Biedl syndrome, people took it or a placebo for 14 weeks, then all took it for a year4. Weight fell in people with Bardet-Biedl syndrome; in Alström syndrome, another rare genetic condition studied in the same trial, the results were inconclusive4. A phase 3 trial called TRANSCEND compared it with placebo for a year in people aged 4 to 66 with acquired hypothalamic obesity5. In that trial, BMI (body-mass index, a measure of weight for height) and hunger fell more on setmelanotide than on placebo5. Most people in the trials had some skin darkening, which the label says goes away after stopping1.

Open questions

  • Effects over longer periods than the trials behind its approval, which ran about a year1.
  • Whether it does anything for general obesity. The label says it isn't expected to, and describes only a short study of energy use in 12 otherwise healthy people with obesity, in whom its safety and effectiveness haven't been established1.
  • Why results differ from one condition to another. Weight loss differed between the POMC and LEPR trials, and results were inconclusive in Alström syndrome34.

Worth knowing

The label warns about depression and suicidal thoughts, sexual side effects including unexpected erections, and serious allergic reactions1. Because it darkens skin, it can also darken existing moles and cause new ones, and the label calls for a full skin check before starting and periodically during treatment1. For acquired hypothalamic obesity, the label adds two warnings1. One is about a sudden shortage of adrenal hormones, which help the body cope with stress (acute adrenal insufficiency), in people whose levels are already low (secondary adrenal insufficiency)1. The other is about blood sodium going too high or too low in people who also have central diabetes insipidus, a shortage of the hormone vasopressin1.

Sources

  1. IMCIVREE (setmelanotide) injection, FDA prescribing information, revised 4/2026 (DailyMed setid 70c3ccf7-4df0-4c75-ba07-fede9970c8d9)
  2. Drugs@FDA: NDA 213793, IMCIVREE (setmelanotide acetate), approval history
  3. Clément K, et al. Efficacy and safety of setmelanotide in individuals with severe obesity due to LEPR or POMC deficiency: single-arm, open-label, multicentre, phase 3 trials. Lancet Diabetes Endocrinol 2020;8:960-970 (PMID 33137293)
  4. Haqq AM, et al. Efficacy and safety of setmelanotide in patients with Bardet-Biedl syndrome and Alström syndrome: phase 3 trial. Lancet Diabetes Endocrinol 2022;10:859-868 (PMID 36356613)
  5. Miller JL, et al. Setmelanotide for the Treatment of Acquired Hypothalamic Obesity (TRANSCEND). N Engl J Med 2026;395(2):138-150 (PMID 42418774)
  6. European Medicines Agency: Imcivree EPAR (page updated 27/05/2026)
  7. IMCIVREE prescribing information as approved 11/2020 (Drugs@FDA label PDF, NDA 213793 ORIG-1)
  8. FDA supplement approval letter, NDA 213793/S-009 (March 19, 2026)

More in Melanocortin peptides